Instil Bio, Inc. (TIL) stock
TILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.24−0.07 (-1.11%)
Close on Nov 12, 2026Market cap $42.32MP/E –Yield –
Instil Bio ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Instil Bio's ebitda for the twelve months ending Jun 30, 2026 was -$36.89M. For fiscal 2025 it was -$78.05M. The highest annual figure on record is -$33.39M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$78.05M | – |
| FY2024 | Dec 31, 2024 | -$69.93M | – |
| FY2023 | Dec 31, 2023 | -$154.41M | – |
| FY2022 | Dec 31, 2022 | -$220.47M | – |
| FY2021 | Dec 31, 2021 | -$152.81M | – |
| FY2020 | Dec 31, 2020 | -$33.39M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.33M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.55M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.01M | – |
| Q2 FY2025 | Jun 30, 2025 | -$23.43M | – |
| Q1 FY2025 | Mar 31, 2025 | -$30.06M | – |
| Q4 FY2024 | Dec 31, 2024 | -$11.08M | – |
| Q3 FY2024 | Sep 30, 2024 | -$22.73M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.16M | – |
| Q1 FY2024 | Mar 31, 2024 | -$22.96M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.98M | – |
| Q3 FY2023 | Sep 30, 2023 | -$65.76M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$56.67M | – |
| Q4 FY2022 | Dec 31, 2022 | -$54.70M | – |
| Q3 FY2022 | Sep 30, 2022 | -$54.71M | – |
| Q2 FY2022 | Jun 30, 2022 | -$57.67M | – |
| Q1 FY2022 | Mar 31, 2022 | -$53.39M | – |
| Q4 FY2021 | Dec 31, 2021 | -$52.86M | – |
| Q3 FY2021 | Sep 30, 2021 | -$42.26M | – |
| Q2 FY2021 | Jun 30, 2021 | -$34.73M | – |
| Q1 FY2021 | Mar 31, 2021 | -$22.96M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.33M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.64M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.56M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.86M | – |
See a number that looks wrong?